Vertex Pharmaceuticals Incorporated (VRTX) 當前追蹤本益比 (P/E) 為 28.3, 前瞻本益比為 23.0. 追蹤盈利收益率為 3.54%, 前瞻盈利收益率 4.34%. PEG 0.89 (Peter Lynch 低估標準 ≤1.0). 葛拉漢數為 $160.48.
本頁證實的標準:
SharesGrow 綜合評分： 84/100 其中 5/7 項標準通過。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -160.2 | 2.00 | 15.52 | 10.54 | - |
| 2017 | 141.5 | -0.43 | 18.38 | 14.99 | - |
| 2018 | 20.1 | 0.03 | 9.50 | 13.83 | - |
| 2019 | 47.8 | -1.07 | 9.24 | 13.50 | - |
| 2020 | 22.6 | 0.18 | 7.07 | 9.90 | - |
| 2021 | 24.2 | -1.87 | 5.60 | 7.47 | - |
| 2022 | 22.3 | 0.52 | 5.32 | 8.28 | - |
| 2023 | 29.0 | 3.48 | 5.96 | 10.62 | - |
| 2024 | -193.6 | 1.69 | 6.32 | 9.41 | - |
| 2025 | 29.3 | -0.03 | 6.21 | 9.60 | - |
| Year | EPS（稀釋） | 營收 | 淨利潤 | 淨利潤率 |
|---|---|---|---|---|
| 2016 | $-0.46 | $1.7B | $-112.05M | -6.6% |
| 2017 | $1.04 | $2.49B | $263.48M | 10.6% |
| 2018 | $8.09 | $3.05B | $2.1B | 68.8% |
| 2019 | $4.51 | $4.16B | $1.18B | 28.3% |
| 2020 | $10.29 | $6.21B | $2.71B | 43.7% |
| 2021 | $9.01 | $7.57B | $2.34B | 30.9% |
| 2022 | $12.82 | $8.93B | $3.32B | 37.2% |
| 2023 | $13.89 | $9.87B | $3.62B | 36.7% |
| 2024 | $-2.08 | $11.02B | $-535.6M | -4.9% |
| 2025 | $15.32 | $12.07B | $3.95B | 32.7% |
| Year | EPS（平均） | EPS 範圍 | 營收（平均） | 營收範圍 | 分析師人數 |
|---|---|---|---|---|---|
| 2026 | $19.32 | $18.23 – $20.14 | $13.03B | $12.36B – $13.24B | 20 |
| 2027 | $22.25 | $20.54 – $24.15 | $14.37B | $13.44B – $16.46B | 18 |
| 2028 | $25.20 | $14.13 – $35.75 | $15.99B | $15.98B – $15.99B | 13 |
| 2029 | $29.57 | $27.31 – $32.79 | $17.85B | $16.8B – $19.34B | 11 |
| 2030 | $33.61 | $31.04 – $37.27 | $19.79B | $18.63B – $21.45B | 5 |
